1. US Department of Health and Human Services Centers for Disease Control and Prevention: Hepatitis C. Available at http://www.cdc.gov/hepatitis/HCV.htm . Accessed October 2008.
2. Parfieniuk A, Jaroszewicz, Flisiak R: Specifically targeted anitiviral therapy for hepatitis C virus. World J Gastroenterol 2007, 13:5673–5681.
3. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147–1171.
4. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al.: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004, 126:1015–1023.
5. Jensen DM, Freilich B, Andreone P, et al.: Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV) in prior nonresponders to pegylated interferon alfa-2b (12KD)/RBV: final efficacy and safety outcomes of the REPEAT study. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; November 2–6, 2007.